{"status": "Succeeded", "recognitionResults": [{"page": 1, "clockwiseOrientation": 359.92, "width": 1700, "height": 2236, "unit": "pixel", "lines": [{"boundingBox": [223, 132, 392, 133, 391, 181, 222, 179], "text": "Takeda", "words": [{"boundingBox": [248, 133, 390, 136, 389, 180, 248, 180], "text": "Takeda"}]}, {"boundingBox": [714, 248, 851, 248, 851, 279, 715, 280], "text": "Annex A", "words": [{"boundingBox": [722, 249, 823, 249, 823, 280, 722, 281], "text": "Annex"}, {"boundingBox": [829, 249, 849, 248, 849, 280, 829, 280], "text": "A"}]}, {"boundingBox": [301, 317, 1266, 316, 1267, 356, 302, 357], "text": "List of revisions to the Summary of Product Characteristics (SinPC)", "words": [{"boundingBox": [309, 321, 366, 321, 366, 355, 309, 355], "text": "List"}, {"boundingBox": [372, 321, 403, 321, 403, 356, 372, 355], "text": "of"}, {"boundingBox": [410, 321, 537, 320, 537, 357, 410, 356], "text": "revisions"}, {"boundingBox": [543, 320, 574, 320, 574, 357, 544, 357], "text": "to"}, {"boundingBox": [581, 320, 627, 320, 627, 357, 581, 357], "text": "the"}, {"boundingBox": [633, 320, 771, 319, 772, 358, 634, 357], "text": "Summary"}, {"boundingBox": [778, 319, 809, 319, 809, 358, 779, 358], "text": "of"}, {"boundingBox": [815, 319, 929, 319, 930, 358, 816, 358], "text": "Product"}, {"boundingBox": [936, 319, 1144, 317, 1145, 358, 937, 358], "text": "Characteristics", "confidence": "Low"}, {"boundingBox": [1151, 317, 1265, 317, 1266, 357, 1152, 358], "text": "(SinPC)", "confidence": "Low"}]}, {"boundingBox": [179, 392, 663, 395, 663, 427, 178, 424], "text": "Section 4.1 - Therapeutic indications", "words": [{"boundingBox": [183, 394, 279, 394, 280, 425, 184, 425], "text": "Section"}, {"boundingBox": [285, 394, 321, 394, 322, 425, 286, 425], "text": "4.1"}, {"boundingBox": [327, 394, 349, 395, 350, 425, 328, 425], "text": "-"}, {"boundingBox": [357, 395, 511, 395, 512, 426, 358, 425], "text": "Therapeutic"}, {"boundingBox": [517, 395, 663, 395, 664, 427, 518, 426], "text": "indications", "confidence": "Low"}]}, {"boundingBox": [183, 425, 1352, 426, 1351, 462, 182, 461], "text": "Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described", "words": [{"boundingBox": [183, 428, 335, 428, 335, 460, 183, 459], "text": "Pioglitazone"}, {"boundingBox": [341, 428, 362, 428, 361, 460, 341, 460], "text": "is"}, {"boundingBox": [368, 428, 481, 428, 480, 461, 368, 460], "text": "indicated"}, {"boundingBox": [487, 428, 513, 428, 513, 461, 487, 461], "text": "as"}, {"boundingBox": [520, 428, 604, 428, 603, 462, 519, 461], "text": "second"}, {"boundingBox": [610, 428, 636, 428, 636, 462, 610, 462], "text": "or"}, {"boundingBox": [643, 428, 700, 428, 700, 462, 642, 462], "text": "third"}, {"boundingBox": [706, 428, 751, 428, 751, 462, 706, 462], "text": "line"}, {"boundingBox": [758, 428, 877, 428, 876, 462, 757, 462], "text": "treatment"}, {"boundingBox": [883, 428, 909, 428, 909, 462, 882, 462], "text": "of"}, {"boundingBox": [916, 428, 969, 428, 968, 462, 915, 462], "text": "type"}, {"boundingBox": [975, 428, 994, 428, 993, 462, 975, 462], "text": "2"}, {"boundingBox": [1000, 428, 1096, 427, 1096, 462, 999, 462], "text": "diabetes"}, {"boundingBox": [1102, 427, 1201, 427, 1200, 461, 1102, 462], "text": "mellitus"}, {"boundingBox": [1207, 427, 1238, 427, 1237, 461, 1206, 461], "text": "as"}, {"boundingBox": [1244, 427, 1353, 426, 1352, 461, 1243, 461], "text": "described"}]}, {"boundingBox": [183, 465, 266, 461, 267, 490, 184, 493], "text": "below:", "words": [{"boundingBox": [182, 463, 263, 460, 265, 489, 183, 492], "text": "below:"}]}, {"boundingBox": [181, 534, 390, 533, 391, 562, 182, 563], "text": "as monotherapy", "words": [{"boundingBox": [185, 538, 211, 537, 210, 560, 184, 559], "text": "as"}, {"boundingBox": [216, 537, 390, 535, 388, 564, 216, 560], "text": "monotherapy"}]}, {"boundingBox": [246, 565, 1229, 564, 1229, 598, 247, 599], "text": "in adult patients (particularly overweight patients) inadequately controlled by diet", "words": [{"boundingBox": [247, 569, 272, 568, 273, 595, 247, 595], "text": "in"}, {"boundingBox": [278, 568, 339, 568, 340, 596, 278, 595], "text": "adult"}, {"boundingBox": [345, 568, 441, 568, 441, 597, 345, 596], "text": "patients"}, {"boundingBox": [446, 568, 597, 567, 598, 599, 446, 597], "text": "(particularly"}, {"boundingBox": [602, 567, 740, 567, 740, 599, 603, 599], "text": "overweight"}, {"boundingBox": [745, 567, 852, 566, 852, 599, 745, 599], "text": "patients)"}, {"boundingBox": [857, 566, 1013, 566, 1014, 599, 857, 599], "text": "inadequately"}, {"boundingBox": [1018, 566, 1142, 565, 1142, 598, 1019, 599], "text": "controlled"}, {"boundingBox": [1147, 565, 1180, 565, 1180, 597, 1148, 598], "text": "by"}, {"boundingBox": [1188, 565, 1228, 565, 1228, 597, 1189, 597], "text": "diet"}]}, {"boundingBox": [241, 599, 1241, 598, 1242, 630, 242, 631], "text": "and exercise for whom metformin is mappropriate because of contraindications or", "words": [{"boundingBox": [248, 601, 294, 601, 294, 628, 248, 627], "text": "and"}, {"boundingBox": [299, 601, 400, 602, 400, 630, 299, 628], "text": "exercise"}, {"boundingBox": [405, 602, 442, 602, 443, 630, 405, 630], "text": "for"}, {"boundingBox": [448, 602, 516, 602, 517, 631, 448, 630], "text": "whom"}, {"boundingBox": [530, 602, 658, 602, 659, 632, 530, 631], "text": "metformin", "confidence": "Low"}, {"boundingBox": [663, 602, 687, 602, 688, 632, 664, 632], "text": "is"}, {"boundingBox": [692, 602, 856, 602, 857, 632, 693, 632], "text": "mappropriate"}, {"boundingBox": [861, 602, 959, 601, 960, 631, 862, 632], "text": "because"}, {"boundingBox": [964, 601, 991, 601, 993, 631, 965, 631], "text": "of"}, {"boundingBox": [996, 601, 1205, 599, 1206, 629, 998, 631], "text": "contraindications"}, {"boundingBox": [1210, 599, 1241, 599, 1242, 628, 1212, 629], "text": "or"}]}, {"boundingBox": [249, 634, 391, 635, 390, 661, 248, 660], "text": "intolerance", "words": [{"boundingBox": [249, 636, 384, 635, 384, 661, 249, 660], "text": "intolerance"}]}, {"boundingBox": [182, 703, 687, 704, 686, 733, 181, 732], "text": "as dual oral therapy in combination with", "words": [{"boundingBox": [184, 704, 212, 704, 212, 732, 184, 731], "text": "as"}, {"boundingBox": [218, 704, 275, 704, 275, 733, 217, 732], "text": "dual"}, {"boundingBox": [281, 704, 335, 704, 335, 733, 280, 733], "text": "oral"}, {"boundingBox": [340, 704, 442, 704, 441, 734, 340, 733], "text": "therapy"}, {"boundingBox": [448, 704, 474, 704, 473, 734, 447, 734], "text": "in"}, {"boundingBox": [479, 704, 632, 704, 631, 733, 478, 734], "text": "combination"}, {"boundingBox": [637, 704, 686, 704, 685, 733, 636, 733], "text": "with"}]}, {"boundingBox": [259, 735, 1214, 732, 1215, 767, 260, 770], "text": "metformin, in adult patients (particularly overweight patients) with insufficient", "words": [{"boundingBox": [260, 737, 389, 736, 389, 770, 260, 769], "text": "metformin,", "confidence": "Low"}, {"boundingBox": [395, 736, 421, 736, 420, 770, 395, 770], "text": "in"}, {"boundingBox": [427, 736, 488, 736, 488, 770, 427, 770], "text": "adult"}, {"boundingBox": [494, 736, 589, 735, 589, 770, 494, 770], "text": "patients"}, {"boundingBox": [596, 735, 745, 735, 745, 770, 596, 770], "text": "(particularly"}, {"boundingBox": [752, 735, 889, 735, 889, 769, 752, 770], "text": "overweight"}, {"boundingBox": [895, 735, 1000, 735, 1001, 768, 895, 769], "text": "patients)"}, {"boundingBox": [1007, 735, 1059, 734, 1060, 767, 1007, 768], "text": "with"}, {"boundingBox": [1066, 734, 1213, 734, 1214, 765, 1066, 767], "text": "insufficient"}]}, {"boundingBox": [247, 769, 1249, 768, 1250, 802, 248, 804], "text": "glycaemia control despite maximal tolerated dose of monotherapy with metformin", "words": [{"boundingBox": [254, 771, 378, 770, 378, 804, 254, 804], "text": "glycaemia", "confidence": "Low"}, {"boundingBox": [385, 770, 476, 770, 476, 804, 385, 804], "text": "control"}, {"boundingBox": [483, 770, 565, 770, 565, 804, 482, 804], "text": "despite"}, {"boundingBox": [572, 770, 678, 769, 678, 804, 571, 804], "text": "maximal"}, {"boundingBox": [685, 769, 796, 769, 795, 804, 684, 804], "text": "tolerated"}, {"boundingBox": [802, 769, 854, 769, 854, 804, 802, 804], "text": "dose"}, {"boundingBox": [861, 769, 887, 769, 887, 804, 860, 804], "text": "of"}, {"boundingBox": [893, 769, 1054, 769, 1054, 803, 893, 804], "text": "monotherapy"}, {"boundingBox": [1061, 769, 1113, 769, 1112, 803, 1060, 803], "text": "with"}, {"boundingBox": [1119, 769, 1250, 770, 1249, 803, 1119, 803], "text": "metformin"}]}, {"boundingBox": [241, 804, 1232, 803, 1233, 835, 242, 836], "text": "a sulphonylurea, only in adult patients who show intolerance to metformin of for", "words": [{"boundingBox": [256, 805, 271, 805, 269, 836, 254, 837], "text": "a"}, {"boundingBox": [277, 805, 456, 804, 455, 836, 275, 836], "text": "sulphonylurea,", "confidence": "Low"}, {"boundingBox": [462, 804, 514, 804, 513, 836, 461, 836], "text": "only"}, {"boundingBox": [520, 804, 547, 804, 547, 836, 519, 836], "text": "in"}, {"boundingBox": [554, 804, 614, 804, 613, 836, 553, 836], "text": "adult", "confidence": "Low"}, {"boundingBox": [620, 804, 716, 804, 716, 836, 620, 836], "text": "patients"}, {"boundingBox": [722, 804, 776, 804, 776, 836, 722, 836], "text": "who"}, {"boundingBox": [783, 804, 845, 804, 845, 836, 782, 836], "text": "show"}, {"boundingBox": [853, 804, 987, 805, 987, 836, 853, 836], "text": "intolerance"}, {"boundingBox": [993, 805, 1018, 805, 1018, 836, 993, 836], "text": "to"}, {"boundingBox": [1024, 805, 1153, 805, 1154, 836, 1025, 836], "text": "metformin"}, {"boundingBox": [1159, 805, 1186, 805, 1187, 836, 1160, 836], "text": "of", "confidence": "Low"}, {"boundingBox": [1193, 805, 1232, 805, 1233, 836, 1194, 836], "text": "for"}]}, {"boundingBox": [254, 838, 1220, 837, 1221, 869, 255, 870], "text": "whom metformin is contraindicated, with insufficient glycaemia control despite", "words": [{"boundingBox": [255, 840, 325, 840, 325, 868, 255, 868], "text": "whom"}, {"boundingBox": [337, 840, 465, 840, 466, 870, 338, 869], "text": "metformin"}, {"boundingBox": [470, 840, 493, 840, 494, 870, 471, 870], "text": "is"}, {"boundingBox": [499, 840, 696, 839, 697, 871, 500, 870], "text": "contraindicated,"}, {"boundingBox": [701, 839, 755, 839, 757, 871, 703, 871], "text": "with"}, {"boundingBox": [761, 839, 901, 839, 902, 871, 762, 871], "text": "insufficient"}, {"boundingBox": [906, 839, 1030, 839, 1031, 870, 907, 871], "text": "glycaemia", "confidence": "Low"}, {"boundingBox": [1035, 839, 1127, 838, 1128, 870, 1037, 870], "text": "control", "confidence": "Low"}, {"boundingBox": [1132, 838, 1218, 838, 1220, 869, 1134, 870], "text": "despite"}]}, {"boundingBox": [237, 872, 1002, 871, 1003, 904, 238, 905], "text": "maximal tolerated dose of monotherapy with a sulphonylurea.", "words": [{"boundingBox": [253, 874, 361, 874, 361, 904, 252, 903], "text": "maximal"}, {"boundingBox": [367, 874, 477, 873, 476, 905, 366, 904], "text": "tolerated"}, {"boundingBox": [483, 873, 538, 873, 538, 905, 482, 905], "text": "dose"}, {"boundingBox": [544, 873, 570, 873, 570, 905, 543, 905], "text": "of"}, {"boundingBox": [576, 873, 738, 872, 737, 905, 575, 905], "text": "monotherapy"}, {"boundingBox": [743, 872, 797, 872, 797, 905, 743, 905], "text": "with"}, {"boundingBox": [803, 872, 820, 872, 819, 905, 803, 905], "text": "a"}, {"boundingBox": [825, 872, 1002, 872, 1002, 904, 825, 905], "text": "sulphonylurea.", "confidence": "Low"}]}, {"boundingBox": [182, 942, 708, 940, 709, 970, 183, 972], "text": "as triple oral therapy in combination with", "words": [{"boundingBox": [184, 942, 210, 942, 209, 972, 183, 973], "text": "as"}, {"boundingBox": [216, 942, 290, 942, 289, 971, 215, 972], "text": "triple"}, {"boundingBox": [296, 942, 347, 942, 347, 971, 295, 971], "text": "oral"}, {"boundingBox": [353, 942, 455, 942, 455, 970, 353, 971], "text": "therapy"}, {"boundingBox": [461, 942, 485, 942, 484, 970, 460, 970], "text": "in"}, {"boundingBox": [491, 942, 644, 942, 644, 970, 490, 970], "text": "combination"}, {"boundingBox": [650, 942, 708, 942, 708, 970, 650, 970], "text": "with"}]}, {"boundingBox": [252, 976, 1309, 974, 1310, 1006, 253, 1008], "text": "metformin and a sulphonylurea, in adult patients (particularly overweight patients) with", "words": [{"boundingBox": [254, 976, 383, 976, 383, 1007, 253, 1005], "text": "metformin"}, {"boundingBox": [389, 976, 435, 976, 434, 1007, 389, 1007], "text": "and"}, {"boundingBox": [441, 976, 456, 976, 455, 1007, 440, 1007], "text": "a"}, {"boundingBox": [462, 976, 641, 976, 640, 1007, 461, 1007], "text": "sulphonylurea,"}, {"boundingBox": [646, 976, 673, 976, 673, 1007, 646, 1007], "text": "in"}, {"boundingBox": [679, 976, 740, 976, 739, 1007, 678, 1007], "text": "adult"}, {"boundingBox": [745, 976, 841, 976, 840, 1007, 745, 1007], "text": "patients"}, {"boundingBox": [846, 976, 997, 976, 997, 1006, 846, 1007], "text": "(particularly"}, {"boundingBox": [1003, 976, 1140, 975, 1140, 1005, 1002, 1006], "text": "overweight"}, {"boundingBox": [1145, 975, 1250, 975, 1250, 1003, 1145, 1005], "text": "patients)"}, {"boundingBox": [1256, 975, 1309, 975, 1309, 1002, 1256, 1003], "text": "with"}]}, {"boundingBox": [251, 1009, 924, 1011, 924, 1041, 250, 1039], "text": "insufficient glycaemia control despite dual oral therapy.", "words": [{"boundingBox": [253, 1012, 395, 1012, 395, 1038, 253, 1037], "text": "insufficient"}, {"boundingBox": [400, 1012, 525, 1011, 525, 1038, 400, 1038], "text": "glycaemia", "confidence": "Low"}, {"boundingBox": [530, 1011, 622, 1011, 622, 1039, 530, 1038], "text": "control"}, {"boundingBox": [627, 1011, 713, 1011, 713, 1040, 627, 1039], "text": "despite"}, {"boundingBox": [719, 1011, 770, 1011, 771, 1040, 720, 1040], "text": "dual"}, {"boundingBox": [775, 1011, 826, 1011, 827, 1040, 776, 1040], "text": "oral"}, {"boundingBox": [831, 1011, 924, 1011, 924, 1041, 832, 1041], "text": "therapy."}]}, {"boundingBox": [189, 1069, 1356, 1068, 1357, 1105, 190, 1106], "text": "Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult", "words": [{"boundingBox": [256, 1073, 408, 1074, 406, 1104, 253, 1101], "text": "Pioglitazone"}, {"boundingBox": [413, 1075, 435, 1075, 433, 1104, 411, 1104], "text": "is"}, {"boundingBox": [441, 1075, 491, 1075, 489, 1105, 439, 1104], "text": "also"}, {"boundingBox": [496, 1075, 610, 1076, 609, 1106, 494, 1105], "text": "indicated"}, {"boundingBox": [615, 1076, 652, 1076, 651, 1106, 614, 1106], "text": "for"}, {"boundingBox": [658, 1076, 810, 1076, 809, 1107, 656, 1106], "text": "combination"}, {"boundingBox": [815, 1076, 870, 1075, 870, 1106, 815, 1107], "text": "with"}, {"boundingBox": [876, 1075, 960, 1075, 960, 1106, 876, 1106], "text": "insulin"}, {"boundingBox": [966, 1075, 990, 1075, 990, 1106, 966, 1106], "text": "in"}, {"boundingBox": [995, 1075, 1052, 1074, 1053, 1105, 995, 1106], "text": "type"}, {"boundingBox": [1058, 1074, 1076, 1074, 1076, 1105, 1058, 1105], "text": "2"}, {"boundingBox": [1081, 1074, 1179, 1072, 1180, 1104, 1082, 1105], "text": "diabetes"}, {"boundingBox": [1184, 1072, 1281, 1071, 1283, 1102, 1185, 1104], "text": "mellitus"}, {"boundingBox": [1287, 1071, 1355, 1069, 1356, 1101, 1288, 1102], "text": "adult"}]}, {"boundingBox": [235, 1111, 1364, 1108, 1365, 1138, 236, 1141], "text": "patients with insufficient glycaemia control on insulin for whom metformin is inappropriate", "words": [{"boundingBox": [255, 1111, 351, 1111, 350, 1139, 254, 1138], "text": "patients", "confidence": "Low"}, {"boundingBox": [356, 1111, 411, 1111, 410, 1139, 356, 1139], "text": "with"}, {"boundingBox": [416, 1111, 556, 1111, 555, 1140, 416, 1139], "text": "insufficient", "confidence": "Low"}, {"boundingBox": [561, 1111, 688, 1111, 688, 1140, 561, 1140], "text": "glycaemia", "confidence": "Low"}, {"boundingBox": [693, 1111, 780, 1111, 780, 1140, 693, 1140], "text": "control"}, {"boundingBox": [786, 1111, 818, 1111, 818, 1140, 786, 1140], "text": "on"}, {"boundingBox": [824, 1111, 907, 1111, 907, 1140, 824, 1140], "text": "insulin"}, {"boundingBox": [913, 1111, 952, 1110, 953, 1139, 913, 1140], "text": "for"}, {"boundingBox": [958, 1110, 1025, 1110, 1025, 1139, 958, 1139], "text": "whom"}, {"boundingBox": [1038, 1110, 1166, 1110, 1167, 1138, 1038, 1139], "text": "metformin"}, {"boundingBox": [1172, 1110, 1193, 1110, 1194, 1138, 1172, 1138], "text": "is"}, {"boundingBox": [1199, 1110, 1364, 1109, 1364, 1136, 1199, 1138], "text": "inappropriate"}]}, {"boundingBox": [238, 1143, 996, 1142, 997, 1173, 239, 1174], "text": "because of contraindications or intolerance (see section 4 4)", "words": [{"boundingBox": [256, 1145, 353, 1145, 351, 1173, 254, 1173], "text": "because"}, {"boundingBox": [359, 1145, 384, 1145, 382, 1173, 357, 1173], "text": "of"}, {"boundingBox": [390, 1145, 601, 1145, 599, 1172, 388, 1173], "text": "contraindications"}, {"boundingBox": [606, 1144, 632, 1144, 631, 1172, 605, 1172], "text": "or"}, {"boundingBox": [637, 1144, 773, 1144, 772, 1173, 636, 1172], "text": "intolerance"}, {"boundingBox": [779, 1144, 830, 1144, 829, 1173, 778, 1173], "text": "(see"}, {"boundingBox": [836, 1144, 924, 1143, 923, 1173, 835, 1173], "text": "section"}, {"boundingBox": [929, 1143, 948, 1143, 947, 1174, 928, 1173], "text": "4", "confidence": "Low"}, {"boundingBox": [953, 1143, 988, 1143, 987, 1174, 952, 1174], "text": "4)", "confidence": "Low"}]}, {"boundingBox": [188, 1208, 1333, 1206, 1334, 1241, 189, 1242], "text": "After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to", "words": [{"boundingBox": [189, 1209, 248, 1209, 249, 1242, 189, 1241], "text": "After"}, {"boundingBox": [254, 1209, 363, 1210, 363, 1242, 255, 1242], "text": "initiation"}, {"boundingBox": [369, 1210, 397, 1210, 397, 1242, 370, 1242], "text": "of"}, {"boundingBox": [403, 1210, 494, 1210, 495, 1242, 404, 1242], "text": "therapy"}, {"boundingBox": [501, 1210, 554, 1210, 555, 1242, 502, 1242], "text": "with"}, {"boundingBox": [560, 1210, 719, 1210, 720, 1242, 561, 1242], "text": "pioglitazone,"}, {"boundingBox": [725, 1210, 823, 1210, 825, 1242, 727, 1242], "text": "patients"}, {"boundingBox": [829, 1210, 908, 1210, 910, 1242, 831, 1242], "text": "should"}, {"boundingBox": [914, 1210, 944, 1210, 946, 1242, 916, 1242], "text": "be"}, {"boundingBox": [950, 1210, 1061, 1209, 1062, 1241, 952, 1242], "text": "reviewed"}, {"boundingBox": [1067, 1209, 1129, 1209, 1130, 1241, 1069, 1241], "text": "after"}, {"boundingBox": [1135, 1209, 1148, 1209, 1150, 1241, 1137, 1241], "text": "3"}, {"boundingBox": [1154, 1209, 1180, 1208, 1181, 1241, 1156, 1241], "text": "to"}, {"boundingBox": [1186, 1208, 1201, 1208, 1203, 1241, 1188, 1241], "text": "6"}, {"boundingBox": [1207, 1208, 1294, 1208, 1296, 1241, 1209, 1241], "text": "months"}, {"boundingBox": [1301, 1208, 1332, 1207, 1334, 1240, 1303, 1241], "text": "to", "confidence": "Low"}]}, {"boundingBox": [174, 1245, 1383, 1242, 1384, 1275, 175, 1277], "text": "assess adequacy of response to treatment (e g. reduction in HbAlc). In patients who fail to show an", "words": [{"boundingBox": [185, 1247, 259, 1247, 259, 1276, 184, 1276], "text": "assess"}, {"boundingBox": [265, 1247, 381, 1246, 381, 1276, 265, 1276], "text": "adequacy"}, {"boundingBox": [386, 1246, 413, 1246, 413, 1276, 386, 1276], "text": "of"}, {"boundingBox": [418, 1246, 525, 1245, 525, 1277, 418, 1276], "text": "response"}, {"boundingBox": [530, 1245, 557, 1245, 557, 1277, 531, 1277], "text": "to"}, {"boundingBox": [562, 1245, 678, 1245, 678, 1277, 562, 1277], "text": "treatment"}, {"boundingBox": [684, 1244, 710, 1244, 710, 1277, 684, 1277], "text": "(e"}, {"boundingBox": [715, 1244, 738, 1244, 738, 1277, 716, 1277], "text": "g.", "confidence": "Low"}, {"boundingBox": [743, 1244, 861, 1244, 862, 1277, 744, 1277], "text": "reduction"}, {"boundingBox": [867, 1244, 891, 1244, 892, 1276, 868, 1277], "text": "in"}, {"boundingBox": [897, 1244, 1003, 1244, 1004, 1276, 897, 1276], "text": "HbAlc).", "confidence": "Low"}, {"boundingBox": [1009, 1244, 1035, 1244, 1036, 1276, 1010, 1276], "text": "In"}, {"boundingBox": [1041, 1244, 1138, 1243, 1139, 1276, 1042, 1276], "text": "patients"}, {"boundingBox": [1144, 1243, 1196, 1243, 1197, 1276, 1145, 1276], "text": "who"}, {"boundingBox": [1201, 1243, 1243, 1243, 1244, 1276, 1203, 1276], "text": "fail"}, {"boundingBox": [1248, 1243, 1274, 1243, 1276, 1275, 1249, 1275], "text": "to"}, {"boundingBox": [1280, 1243, 1340, 1243, 1341, 1275, 1281, 1275], "text": "show"}, {"boundingBox": [1349, 1243, 1381, 1243, 1382, 1275, 1350, 1275], "text": "an"}]}, {"boundingBox": [187, 1277, 1357, 1275, 1358, 1309, 188, 1312], "text": "adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged", "words": [{"boundingBox": [188, 1280, 292, 1279, 292, 1310, 188, 1310], "text": "adequate"}, {"boundingBox": [298, 1279, 411, 1279, 411, 1311, 298, 1310], "text": "response,"}, {"boundingBox": [417, 1279, 568, 1278, 568, 1311, 417, 1311], "text": "pioglitazone"}, {"boundingBox": [574, 1278, 654, 1277, 654, 1311, 574, 1311], "text": "should"}, {"boundingBox": [660, 1277, 696, 1277, 696, 1311, 660, 1311], "text": "be"}, {"boundingBox": [702, 1277, 862, 1277, 862, 1311, 702, 1311], "text": "discontinued."}, {"boundingBox": [868, 1277, 894, 1277, 894, 1311, 868, 1311], "text": "In"}, {"boundingBox": [900, 1277, 956, 1276, 956, 1311, 899, 1311], "text": "light"}, {"boundingBox": [962, 1276, 988, 1276, 988, 1311, 962, 1311], "text": "of"}, {"boundingBox": [994, 1276, 1100, 1276, 1099, 1310, 994, 1311], "text": "potential"}, {"boundingBox": [1106, 1276, 1166, 1276, 1166, 1310, 1105, 1310], "text": "risks"}, {"boundingBox": [1172, 1276, 1225, 1276, 1225, 1310, 1172, 1310], "text": "with"}, {"boundingBox": [1231, 1276, 1357, 1276, 1356, 1309, 1231, 1310], "text": "prolonged"}]}, {"boundingBox": [176, 1311, 1380, 1309, 1381, 1343, 177, 1345], "text": "therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is", "words": [{"boundingBox": [183, 1312, 282, 1312, 280, 1345, 181, 1345], "text": "therapy,", "confidence": "Low"}, {"boundingBox": [289, 1312, 423, 1312, 421, 1345, 287, 1345], "text": "prescribers"}, {"boundingBox": [429, 1312, 509, 1312, 508, 1345, 428, 1345], "text": "should"}, {"boundingBox": [516, 1312, 611, 1312, 610, 1345, 514, 1345], "text": "confirm"}, {"boundingBox": [620, 1312, 643, 1312, 642, 1345, 618, 1345], "text": "at"}, {"boundingBox": [650, 1312, 784, 1312, 783, 1345, 649, 1345], "text": "subsequent"}, {"boundingBox": [790, 1312, 877, 1311, 876, 1345, 790, 1345], "text": "routine"}, {"boundingBox": [883, 1311, 976, 1311, 976, 1345, 883, 1345], "text": "reviews"}, {"boundingBox": [983, 1311, 1031, 1311, 1030, 1345, 982, 1345], "text": "that"}, {"boundingBox": [1037, 1311, 1074, 1311, 1073, 1345, 1036, 1345], "text": "the"}, {"boundingBox": [1080, 1311, 1165, 1310, 1164, 1344, 1080, 1345], "text": "benefit"}, {"boundingBox": [1171, 1310, 1197, 1310, 1197, 1344, 1171, 1344], "text": "of"}, {"boundingBox": [1204, 1310, 1353, 1310, 1353, 1344, 1203, 1344], "text": "pioglitazone"}, {"boundingBox": [1359, 1310, 1381, 1310, 1381, 1344, 1359, 1344], "text": "is"}]}, {"boundingBox": [167, 1344, 554, 1342, 555, 1379, 168, 1381], "text": "maintained (see section 4.4)", "words": [{"boundingBox": [183, 1350, 319, 1345, 317, 1375, 181, 1379], "text": "maintained", "confidence": "Low"}, {"boundingBox": [325, 1344, 377, 1344, 375, 1375, 323, 1375], "text": "(see"}, {"boundingBox": [383, 1344, 468, 1344, 466, 1377, 380, 1375], "text": "section"}, {"boundingBox": [474, 1345, 532, 1346, 529, 1380, 472, 1377], "text": "4.4)", "confidence": "Low"}]}, {"boundingBox": [186, 1415, 864, 1418, 863, 1447, 185, 1445], "text": "Section 4.2 - Posology and method of administration", "words": [{"boundingBox": [188, 1416, 277, 1417, 278, 1445, 189, 1443], "text": "Section"}, {"boundingBox": [288, 1417, 324, 1417, 324, 1445, 288, 1445], "text": "4.2"}, {"boundingBox": [329, 1417, 347, 1417, 347, 1445, 330, 1445], "text": "-"}, {"boundingBox": [354, 1417, 468, 1418, 469, 1446, 355, 1445], "text": "Posology"}, {"boundingBox": [474, 1418, 525, 1418, 526, 1447, 474, 1446], "text": "and"}, {"boundingBox": [531, 1418, 631, 1418, 631, 1447, 531, 1447], "text": "method"}, {"boundingBox": [636, 1418, 663, 1418, 663, 1447, 637, 1447], "text": "of"}, {"boundingBox": [668, 1418, 861, 1418, 862, 1446, 669, 1447], "text": "administration"}]}, {"boundingBox": [181, 1447, 275, 1445, 276, 1476, 182, 1477], "text": "Elderly", "words": [{"boundingBox": [185, 1447, 275, 1447, 275, 1475, 184, 1476], "text": "Elderly"}]}, {"boundingBox": [179, 1479, 1393, 1480, 1392, 1511, 178, 1510], "text": "Physicians should start treatment with the lowest available dose and increase the dose gradually,", "words": [{"boundingBox": [184, 1482, 320, 1482, 319, 1510, 183, 1509], "text": "Physicians"}, {"boundingBox": [325, 1482, 411, 1481, 410, 1510, 324, 1510], "text": "should"}, {"boundingBox": [416, 1481, 474, 1481, 473, 1511, 415, 1510], "text": "start"}, {"boundingBox": [479, 1481, 598, 1481, 597, 1511, 478, 1511], "text": "treatment"}, {"boundingBox": [604, 1481, 660, 1481, 658, 1511, 602, 1511], "text": "with"}, {"boundingBox": [668, 1481, 710, 1481, 709, 1512, 667, 1511], "text": "the"}, {"boundingBox": [716, 1481, 801, 1480, 800, 1512, 714, 1512], "text": "lowest"}, {"boundingBox": [806, 1480, 920, 1480, 919, 1512, 805, 1512], "text": "available"}, {"boundingBox": [932, 1480, 987, 1480, 985, 1512, 931, 1512], "text": "dose"}, {"boundingBox": [994, 1480, 1043, 1480, 1041, 1512, 992, 1512], "text": "and"}, {"boundingBox": [1048, 1480, 1149, 1480, 1148, 1512, 1047, 1512], "text": "increase"}, {"boundingBox": [1156, 1480, 1198, 1480, 1197, 1512, 1155, 1512], "text": "the"}, {"boundingBox": [1209, 1480, 1265, 1480, 1263, 1511, 1207, 1512], "text": "dose"}, {"boundingBox": [1272, 1480, 1393, 1480, 1391, 1511, 1270, 1511], "text": "gradually,"}]}, {"boundingBox": [177, 1516, 1397, 1514, 1397, 1546, 178, 1548], "text": "particularly when pioglitazone is used in combination with insulin (see section 4 4 Fluid retention", "words": [{"boundingBox": [183, 1519, 326, 1518, 326, 1546, 183, 1545], "text": "particularly"}, {"boundingBox": [335, 1518, 400, 1518, 400, 1547, 335, 1546], "text": "when"}, {"boundingBox": [408, 1518, 561, 1517, 561, 1547, 408, 1547], "text": "pioglitazone"}, {"boundingBox": [567, 1517, 591, 1517, 591, 1548, 567, 1548], "text": "is"}, {"boundingBox": [596, 1517, 658, 1517, 658, 1548, 596, 1548], "text": "used"}, {"boundingBox": [663, 1517, 690, 1517, 690, 1548, 663, 1548], "text": "in"}, {"boundingBox": [698, 1517, 851, 1516, 851, 1548, 698, 1548], "text": "combination"}, {"boundingBox": [860, 1516, 915, 1516, 915, 1548, 860, 1548], "text": "with"}, {"boundingBox": [923, 1516, 1006, 1516, 1006, 1548, 923, 1548], "text": "insulin"}, {"boundingBox": [1015, 1516, 1069, 1515, 1069, 1547, 1015, 1548], "text": "(see"}, {"boundingBox": [1074, 1515, 1162, 1515, 1162, 1547, 1075, 1547], "text": "section"}, {"boundingBox": [1168, 1515, 1185, 1515, 1185, 1547, 1168, 1547], "text": "4"}, {"boundingBox": [1190, 1515, 1206, 1515, 1206, 1547, 1191, 1547], "text": "4", "confidence": "Low"}, {"boundingBox": [1212, 1515, 1278, 1515, 1278, 1547, 1212, 1547], "text": "Fluid"}, {"boundingBox": [1284, 1515, 1393, 1514, 1393, 1546, 1284, 1547], "text": "retention"}]}, {"boundingBox": [176, 1551, 425, 1553, 424, 1581, 175, 1579], "text": "and cardiac failure)", "words": [{"boundingBox": [184, 1553, 230, 1553, 229, 1579, 183, 1579], "text": "and"}, {"boundingBox": [235, 1553, 325, 1553, 324, 1581, 234, 1579], "text": "cardiac"}, {"boundingBox": [330, 1553, 424, 1553, 424, 1582, 329, 1581], "text": "failure)"}]}, {"boundingBox": [181, 1616, 629, 1617, 628, 1652, 180, 1650], "text": "Section 4.3 - Contraindications", "words": [{"boundingBox": [186, 1618, 281, 1617, 281, 1650, 185, 1652], "text": "Section"}, {"boundingBox": [288, 1617, 324, 1617, 323, 1649, 287, 1649], "text": "4.3"}, {"boundingBox": [330, 1617, 344, 1617, 343, 1649, 330, 1649], "text": "-"}, {"boundingBox": [350, 1617, 593, 1620, 592, 1651, 350, 1649], "text": "Contraindications", "confidence": "Low"}]}, {"boundingBox": [252, 1652, 890, 1653, 889, 1685, 251, 1684], "text": "current bladder cancer or a history of bladder cancer", "words": [{"boundingBox": [256, 1656, 343, 1654, 342, 1683, 256, 1683], "text": "current"}, {"boundingBox": [348, 1654, 440, 1653, 440, 1683, 348, 1683], "text": "bladder"}, {"boundingBox": [445, 1653, 527, 1653, 526, 1683, 445, 1683], "text": "cancer"}, {"boundingBox": [532, 1653, 561, 1653, 561, 1683, 532, 1683], "text": "or"}, {"boundingBox": [566, 1653, 579, 1653, 579, 1683, 566, 1683], "text": "a"}, {"boundingBox": [584, 1653, 671, 1653, 671, 1683, 584, 1683], "text": "history"}, {"boundingBox": [676, 1653, 703, 1653, 703, 1684, 676, 1684], "text": "of"}, {"boundingBox": [709, 1653, 803, 1653, 802, 1684, 708, 1684], "text": "bladder"}, {"boundingBox": [808, 1653, 889, 1654, 889, 1685, 808, 1685], "text": "cancer"}]}, {"boundingBox": [251, 1691, 737, 1690, 738, 1715, 252, 1716], "text": "uninvestigated macroscopic haematuria", "words": [{"boundingBox": [253, 1693, 432, 1691, 432, 1716, 254, 1716], "text": "uninvestigated", "confidence": "Low"}, {"boundingBox": [439, 1691, 593, 1691, 594, 1716, 440, 1716], "text": "macroscopic"}, {"boundingBox": [597, 1691, 734, 1691, 735, 1716, 598, 1716], "text": "haematuria", "confidence": "Low"}]}, {"boundingBox": [189, 1754, 885, 1755, 884, 1787, 188, 1785], "text": "Section 4.4 - Special warnings and precautions for use", "words": [{"boundingBox": [189, 1754, 280, 1756, 280, 1785, 189, 1784], "text": "Section"}, {"boundingBox": [288, 1756, 323, 1757, 323, 1785, 288, 1785], "text": "4.4"}, {"boundingBox": [329, 1757, 348, 1757, 348, 1785, 329, 1785], "text": "-"}, {"boundingBox": [354, 1757, 448, 1758, 448, 1786, 354, 1785], "text": "Special"}, {"boundingBox": [453, 1758, 572, 1759, 572, 1786, 454, 1786], "text": "warnings"}, {"boundingBox": [578, 1759, 629, 1759, 629, 1786, 578, 1786], "text": "and"}, {"boundingBox": [634, 1759, 786, 1758, 787, 1786, 635, 1786], "text": "precautions"}, {"boundingBox": [792, 1758, 833, 1758, 833, 1785, 792, 1786], "text": "for"}, {"boundingBox": [839, 1758, 883, 1757, 884, 1785, 839, 1785], "text": "use"}]}, {"boundingBox": [177, 1787, 276, 1786, 277, 1816, 178, 1817], "text": "Elderly", "words": [{"boundingBox": [186, 1788, 277, 1787, 277, 1816, 186, 1816], "text": "Elderly"}]}, {"boundingBox": [183, 1822, 1380, 1821, 1380, 1853, 184, 1854], "text": "Combination use with insulin should be considered with caution in the elderly because of increased", "words": [{"boundingBox": [186, 1823, 342, 1823, 343, 1853, 187, 1851], "text": "Combination"}, {"boundingBox": [348, 1823, 390, 1823, 391, 1853, 348, 1853], "text": "use"}, {"boundingBox": [396, 1823, 452, 1823, 452, 1853, 397, 1853], "text": "with"}, {"boundingBox": [457, 1823, 541, 1824, 542, 1854, 458, 1853], "text": "insulin"}, {"boundingBox": [547, 1824, 629, 1824, 629, 1854, 547, 1854], "text": "should"}, {"boundingBox": [634, 1824, 666, 1824, 666, 1854, 635, 1854], "text": "be"}, {"boundingBox": [672, 1824, 804, 1823, 804, 1854, 672, 1854], "text": "considered"}, {"boundingBox": [809, 1823, 865, 1823, 865, 1854, 810, 1854], "text": "with"}, {"boundingBox": [871, 1823, 960, 1823, 960, 1854, 871, 1854], "text": "caution"}, {"boundingBox": [966, 1823, 990, 1823, 990, 1854, 966, 1854], "text": "in"}, {"boundingBox": [995, 1823, 1036, 1823, 1036, 1854, 996, 1854], "text": "the"}, {"boundingBox": [1042, 1823, 1126, 1822, 1126, 1853, 1042, 1854], "text": "elderly"}, {"boundingBox": [1131, 1822, 1228, 1822, 1228, 1852, 1131, 1853], "text": "because"}, {"boundingBox": [1234, 1822, 1260, 1822, 1260, 1852, 1234, 1852], "text": "of"}, {"boundingBox": [1265, 1822, 1379, 1821, 1379, 1851, 1265, 1852], "text": "increased"}]}, {"boundingBox": [168, 1856, 520, 1859, 519, 1891, 167, 1888], "text": "\"risk of serious heart failure.", "words": [{"boundingBox": [168, 1860, 232, 1859, 233, 1887, 169, 1887], "text": "\"risk", "confidence": "Low"}, {"boundingBox": [238, 1859, 264, 1859, 265, 1887, 238, 1887], "text": "of"}, {"boundingBox": [270, 1859, 358, 1859, 358, 1887, 270, 1887], "text": "serious"}, {"boundingBox": [364, 1859, 426, 1859, 426, 1888, 364, 1887], "text": "heart"}, {"boundingBox": [431, 1859, 520, 1860, 519, 1891, 431, 1889], "text": "failure.", "confidence": "Low"}]}, {"boundingBox": [85, 2149, 537, 2148, 538, 2175, 85, 2176], "text": "Confidential - Subject to Protective Order", "words": [{"boundingBox": [90, 2149, 218, 2150, 219, 2176, 91, 2176], "text": "Confidential"}, {"boundingBox": [223, 2150, 239, 2150, 240, 2176, 224, 2176], "text": "-", "confidence": "Low"}, {"boundingBox": [244, 2150, 322, 2150, 323, 2176, 245, 2176], "text": "Subject"}, {"boundingBox": [328, 2150, 350, 2150, 351, 2176, 328, 2176], "text": "to"}, {"boundingBox": [356, 2150, 464, 2150, 464, 2175, 356, 2176], "text": "Protective", "confidence": "Low"}, {"boundingBox": [469, 2150, 537, 2150, 538, 2175, 470, 2175], "text": "Order"}]}, {"boundingBox": [1212, 2144, 1487, 2144, 1487, 2173, 1213, 2174], "text": "\"TAK-TYNANJ-00213201", "words": [{"boundingBox": [1213, 2146, 1487, 2144, 1486, 2175, 1214, 2174], "text": "\"TAK-TYNANJ-00213201"}]}, {"boundingBox": [376, 2194, 1318, 2192, 1319, 2230, 377, 2232], "text": "Source: https://www.indup54qcooog4ts.ucsf.edu/docs/psjf0226", "words": [{"boundingBox": [383, 2197, 498, 2196, 499, 2231, 384, 2230], "text": "Source:"}, {"boundingBox": [504, 2196, 1318, 2193, 1319, 2230, 505, 2231], "text": "https://www.indup54qcooog4ts.ucsf.edu/docs/psjf0226", "confidence": "Low"}]}]}]}